We are analyzing https://link.springer.com/article/10.1007/s12185-010-0706-6.

Title:
Expanded distribution of the T315I mutation among hematopoietic stem cells and progenitors in a chronic myeloid leukemia patient during imatinib treatment | International Journal of Hematology
Description:
T315I mutation of the ABL-kinase domain in chronic myeloid leukemia (CML) confers resistance to imatinib (IM) as well as second-generation tyrosine kinase inhibitors (TKIs). We report a chronic-phase CML patient undergoing IM treatment, who showed the overt existence of the T315I mutation after 15 months. We retrospectively analyzed the distribution of the T315I mutation using the invader assay and direct DNA sequencing among FACSAria-sorted populations from bone marrow cells: total mononuclear cells (TMC), hematopoietic stem cells (HSC)/Thy-1+, HSC/Thy-1−, common myeloid progenitors (CMP), granulocyte macrophage progenitors (GMP), and megakaryocyte erythroid progenitors (MEP), at 0, 3, 6, 9, and 12 months after IM treatment. T315I was barely detectable by 12 months in TMC, but detectable in 19.2% of HSC/Thy-1− and 46.4% of MEP at diagnosis, and finally expanded into all populations. These results suggest that the monitoring of gene mutations in HSC and progenitors at diagnosis might be helpful for the early detection of TKI-resistant CML patients and facilitate appropriate therapeutic decision.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Health & Fitness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,642,828 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

article, leukemia, chronic, myeloid, imatinib, pubmed, google, scholar, mutation, cells, cas, stem, progenitors, minami, bcrabl, privacy, cookies, content, journal, cml, access, nagoya, information, publish, research, search, hematology, hematopoietic, treatment, kajiguchi, abe, resistance, kinase, patients, therapy, data, log, expanded, distribution, patient, october, yosuke, tyrosine, months, hscthy, diagnosis, gene, mutations, discover, leukaemia,

Topics {✒️}

bcr-abl-kinase domain occur month download article/chapter bcr-abl mutation status bcr-abl t315i mutation bcr-abl gene bcr-abl kinase mutations tki-resistant cml patients chronic myeloid leukemia article international journal abl-kinase domain bcr-abl transcript chronic myelogenous leukemia privacy choices/manage cookies full article pdf related subjects common myeloid progenitors mutation conferring resistance hematopoietic stem cells cancer stem cells progression-inhibitory effect bone marrow cells total mononuclear cells gene mutations blast-crisis cml direct dna sequencing natl cancer inst tosei general hospital kajiguchi contributed equally nagoya university school conditions privacy policy european economic area journal finder publish granulocyte macrophage progenitors megakaryocyte erythroid progenitors granulocyte-macrophage progenitors accepting optional cookies toshihito ohno facsaria-sorted populations author information authors t315i mutation check access instant access article minami article log im treatment tomohiro kajiguchi akihiro abe scientific research imatinib treatment article cite

Questions {❓}

BCR-ABL kinase mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy?
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Expanded distribution of the T315I mutation among hematopoietic stem cells and progenitors in a chronic myeloid leukemia patient during imatinib treatment
         description:T315I mutation of the ABL-kinase domain in chronic myeloid leukemia (CML) confers resistance to imatinib (IM) as well as second-generation tyrosine kinase inhibitors (TKIs). We report a chronic-phase CML patient undergoing IM treatment, who showed the overt existence of the T315I mutation after 15 months. We retrospectively analyzed the distribution of the T315I mutation using the invader assay and direct DNA sequencing among FACSAria-sorted populations from bone marrow cells: total mononuclear cells (TMC), hematopoietic stem cells (HSC)/Thy-1+, HSC/Thy-1−, common myeloid progenitors (CMP), granulocyte macrophage progenitors (GMP), and megakaryocyte erythroid progenitors (MEP), at 0, 3, 6, 9, and 12 months after IM treatment. T315I was barely detectable by 12 months in TMC, but detectable in 19.2% of HSC/Thy-1− and 46.4% of MEP at diagnosis, and finally expanded into all populations. These results suggest that the monitoring of gene mutations in HSC and progenitors at diagnosis might be helpful for the early detection of TKI-resistant CML patients and facilitate appropriate therapeutic decision.
         datePublished:2010-10-22T00:00:00Z
         dateModified:2010-10-22T00:00:00Z
         pageStart:664
         pageEnd:666
         sameAs:https://doi.org/10.1007/s12185-010-0706-6
         keywords:
            Chronic myeloid leukemia
            Imatinib
            T315I
            BCR-ABL
            Hematology
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12185-010-0706-6/MediaObjects/12185_2010_706_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12185-010-0706-6/MediaObjects/12185_2010_706_Fig2_HTML.gif
         isPartOf:
            name:International Journal of Hematology
            issn:
               1865-3774
               0925-5710
            volumeNumber:92
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Japan
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Yosuke Minami
               affiliation:
                     name:Nagoya University Graduate School of Medicine
                     address:
                        name:Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Tomohiro Kajiguchi
               affiliation:
                     name:Tosei General Hospital
                     address:
                        name:Department of Hematology, Tosei General Hospital, Seto, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Akihiro Abe
               affiliation:
                     name:Nagoya University Graduate School of Medicine
                     address:
                        name:Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Toshihito Ohno
               affiliation:
                     name:Tosei General Hospital
                     address:
                        name:Department of Hematology, Tosei General Hospital, Seto, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hitoshi Kiyoi
               affiliation:
                     name:Nagoya University School of Medicine
                     address:
                        name:Department of Infectious Disease, Nagoya University School of Medicine, Nagoya, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Tomoki Naoe
               affiliation:
                     name:Nagoya University Graduate School of Medicine
                     address:
                        name:Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Expanded distribution of the T315I mutation among hematopoietic stem cells and progenitors in a chronic myeloid leukemia patient during imatinib treatment
      description:T315I mutation of the ABL-kinase domain in chronic myeloid leukemia (CML) confers resistance to imatinib (IM) as well as second-generation tyrosine kinase inhibitors (TKIs). We report a chronic-phase CML patient undergoing IM treatment, who showed the overt existence of the T315I mutation after 15 months. We retrospectively analyzed the distribution of the T315I mutation using the invader assay and direct DNA sequencing among FACSAria-sorted populations from bone marrow cells: total mononuclear cells (TMC), hematopoietic stem cells (HSC)/Thy-1+, HSC/Thy-1−, common myeloid progenitors (CMP), granulocyte macrophage progenitors (GMP), and megakaryocyte erythroid progenitors (MEP), at 0, 3, 6, 9, and 12 months after IM treatment. T315I was barely detectable by 12 months in TMC, but detectable in 19.2% of HSC/Thy-1− and 46.4% of MEP at diagnosis, and finally expanded into all populations. These results suggest that the monitoring of gene mutations in HSC and progenitors at diagnosis might be helpful for the early detection of TKI-resistant CML patients and facilitate appropriate therapeutic decision.
      datePublished:2010-10-22T00:00:00Z
      dateModified:2010-10-22T00:00:00Z
      pageStart:664
      pageEnd:666
      sameAs:https://doi.org/10.1007/s12185-010-0706-6
      keywords:
         Chronic myeloid leukemia
         Imatinib
         T315I
         BCR-ABL
         Hematology
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12185-010-0706-6/MediaObjects/12185_2010_706_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12185-010-0706-6/MediaObjects/12185_2010_706_Fig2_HTML.gif
      isPartOf:
         name:International Journal of Hematology
         issn:
            1865-3774
            0925-5710
         volumeNumber:92
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Japan
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Yosuke Minami
            affiliation:
                  name:Nagoya University Graduate School of Medicine
                  address:
                     name:Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Tomohiro Kajiguchi
            affiliation:
                  name:Tosei General Hospital
                  address:
                     name:Department of Hematology, Tosei General Hospital, Seto, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Akihiro Abe
            affiliation:
                  name:Nagoya University Graduate School of Medicine
                  address:
                     name:Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Toshihito Ohno
            affiliation:
                  name:Tosei General Hospital
                  address:
                     name:Department of Hematology, Tosei General Hospital, Seto, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hitoshi Kiyoi
            affiliation:
                  name:Nagoya University School of Medicine
                  address:
                     name:Department of Infectious Disease, Nagoya University School of Medicine, Nagoya, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Tomoki Naoe
            affiliation:
                  name:Nagoya University Graduate School of Medicine
                  address:
                     name:Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:International Journal of Hematology
      issn:
         1865-3774
         0925-5710
      volumeNumber:92
Organization:
      name:Springer Japan
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Nagoya University Graduate School of Medicine
      address:
         name:Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
         type:PostalAddress
      name:Tosei General Hospital
      address:
         name:Department of Hematology, Tosei General Hospital, Seto, Japan
         type:PostalAddress
      name:Nagoya University Graduate School of Medicine
      address:
         name:Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
         type:PostalAddress
      name:Tosei General Hospital
      address:
         name:Department of Hematology, Tosei General Hospital, Seto, Japan
         type:PostalAddress
      name:Nagoya University School of Medicine
      address:
         name:Department of Infectious Disease, Nagoya University School of Medicine, Nagoya, Japan
         type:PostalAddress
      name:Nagoya University Graduate School of Medicine
      address:
         name:Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Yosuke Minami
      affiliation:
            name:Nagoya University Graduate School of Medicine
            address:
               name:Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Tomohiro Kajiguchi
      affiliation:
            name:Tosei General Hospital
            address:
               name:Department of Hematology, Tosei General Hospital, Seto, Japan
               type:PostalAddress
            type:Organization
      name:Akihiro Abe
      affiliation:
            name:Nagoya University Graduate School of Medicine
            address:
               name:Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
               type:PostalAddress
            type:Organization
      name:Toshihito Ohno
      affiliation:
            name:Tosei General Hospital
            address:
               name:Department of Hematology, Tosei General Hospital, Seto, Japan
               type:PostalAddress
            type:Organization
      name:Hitoshi Kiyoi
      affiliation:
            name:Nagoya University School of Medicine
            address:
               name:Department of Infectious Disease, Nagoya University School of Medicine, Nagoya, Japan
               type:PostalAddress
            type:Organization
      name:Tomoki Naoe
      affiliation:
            name:Nagoya University Graduate School of Medicine
            address:
               name:Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
      name:Department of Hematology, Tosei General Hospital, Seto, Japan
      name:Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
      name:Department of Hematology, Tosei General Hospital, Seto, Japan
      name:Department of Infectious Disease, Nagoya University School of Medicine, Nagoya, Japan
      name:Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(66)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.87s.

LINK . SPRINGER . COM {}